Ibrance — Revenues:
Pfizer Ibrance — Revenues: decreased by 3.0% to $1.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.2%, from $977.00M to $1.01B. Over 4 years (FY 2021 to FY 2025), Ibrance — Revenues: shows a downward trend with a -6.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercial execution for the drug, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated by a specific oncology product line within the pharmaceutical por...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic franchises at other major pharmaceutical companies, often evaluated against patent expiry timelines.
pfe_segment_ibrance_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.40B | $1.38B | $1.40B | $1.24B | $1.32B | $1.28B | $1.28B | $1.14B | $1.25B | $1.24B | $1.12B | $1.05B | $1.13B | $1.09B | $1.10B | $977.00M | $1.05B | $1.06B | $1.04B | $1.01B |
| QoQ Change | — | -1.6% | +1.2% | -11.5% | +6.7% | -2.8% | -0.3% | -10.6% | +9.0% | -0.2% | -10.1% | -5.7% | +7.2% | -3.8% | +0.7% | -10.8% | +7.4% | +0.8% | -1.7% | -3.0% |
| YoY Change | — | — | — | — | -6.0% | -7.1% | -8.5% | -7.5% | -5.5% | -3.0% | -12.6% | -7.9% | -9.4% | -12.6% | -2.1% | -7.3% | -7.2% | -2.8% | -5.1% | +3.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's ibrance — revenues:?
- Pfizer (PFE) reported ibrance — revenues: of $1.01B in Q1 2026.
- How has Pfizer's ibrance — revenues: changed year-over-year?
- Pfizer's ibrance — revenues: increased by 3.2% year-over-year, from $977.00M to $1.01B.
- What is the long-term trend for Pfizer's ibrance — revenues:?
- Over 4 years (2021 to 2025), Pfizer's ibrance — revenues: has grown at a -6.7% compound annual growth rate (CAGR), from $5.44B to $4.12B.
- What does ibrance — revenues: mean?
- The total revenue generated from the sales of a specific cancer medication product line.